loading
Schlusskurs vom Vortag:
$30.62
Offen:
$30.14
24-Stunden-Volumen:
662.06K
Relative Volume:
0.45
Marktkapitalisierung:
$3.71B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-10.66
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+6.35%
1M Leistung:
+4.62%
6M Leistung:
-28.76%
1J Leistung:
+4.02%
1-Tages-Spanne:
Value
$29.44
$31.00
1-Wochen-Bereich:
Value
$28.77
$31.77
52-Wochen-Spanne:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Firmenname
Avidity Biosciences Inc
Name
Telefon
858-401-7900
Name
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
391
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
RNA's Discussions on Twitter

Vergleichen Sie RNA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNA
Avidity Biosciences Inc
30.81 3.49B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet Citigroup Buy
2025-03-12 Eingeleitet BMO Capital Markets Outperform
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-12-20 Eingeleitet H.C. Wainwright Buy
2024-11-26 Eingeleitet RBC Capital Mkts Outperform
2024-09-24 Eingeleitet Goldman Buy
2024-08-28 Eingeleitet Barclays Overweight
2024-05-03 Eingeleitet BofA Securities Buy
2024-03-14 Eingeleitet Cantor Fitzgerald Overweight
2023-05-22 Hochstufung Evercore ISI In-line → Outperform
2023-03-31 Herabstufung Evercore ISI Outperform → In-line
2022-07-20 Eingeleitet Chardan Capital Markets Buy
2022-07-12 Eingeleitet Raymond James Strong Buy
2021-09-07 Eingeleitet Evercore ISI Outperform
2021-06-17 Eingeleitet Needham Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-07-07 Eingeleitet Cowen Outperform
2020-07-07 Eingeleitet Credit Suisse Outperform
2020-07-07 Eingeleitet SVB Leerink Outperform
2020-07-07 Eingeleitet Wells Fargo Overweight
Alle ansehen

Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten

pulisher
May 21, 2025

Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan

May 21, 2025
pulisher
May 14, 2025

When (RNA) Moves Investors should Listen - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

Avidity Biosciences Reports Q1 2025 Earnings - TipRanks

May 14, 2025
pulisher
May 13, 2025

Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald

May 12, 2025
pulisher
May 12, 2025

Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus

May 12, 2025
pulisher
May 10, 2025

Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 10, 2025
pulisher
May 09, 2025

Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace

May 09, 2025
pulisher
May 08, 2025

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

12 Analysts Assess Avidity Biosciences: What You Need To Know - Benzinga

May 07, 2025
pulisher
May 06, 2025

RNA Therapeutics Pioneer Avidity Biosciences Takes Stage at Major Bank of America Healthcare Conference - Stock Titan

May 06, 2025
pulisher
May 04, 2025

(RNA) Investment Report - news.stocktradersdaily.com

May 04, 2025
pulisher
May 03, 2025

Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com South Africa

May 03, 2025
pulisher
May 03, 2025

Avidity Biosciences chief program officer sells $190k in stock - Investing.com Australia

May 03, 2025
pulisher
Apr 30, 2025

Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada

Apr 30, 2025
pulisher
Apr 29, 2025

Avidity Biosciences appoints Deloitte as new auditor - Investing.com

Apr 29, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 22, 2025

Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus

Apr 22, 2025
pulisher
Apr 21, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times

Apr 21, 2025
pulisher
Apr 18, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 15, 2025

Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News

Apr 15, 2025
pulisher
Apr 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga

Apr 09, 2025
pulisher
Apr 08, 2025

Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com

Apr 07, 2025
pulisher
Apr 06, 2025

Avidity Biosciences chief program officer sells shares worth $206,799 - MSN

Apr 06, 2025
pulisher
Apr 06, 2025

Avidity Biosciences CFO sells $93,985 in stock - MSN

Apr 06, 2025
pulisher
Apr 05, 2025

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN

Apr 05, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq

Apr 03, 2025
pulisher
Apr 02, 2025

When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 02, 2025

Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Exclusive Look: Avidity Biosciences Reveals Latest Strategy at Needham Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India

Mar 31, 2025

Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):